266 related articles for article (PubMed ID: 26825700)
1. Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?
Bansal A; Radich J
Curr Opin Hematol; 2016 Mar; 23(2):115-20. PubMed ID: 26825700
[TBL] [Abstract][Full Text] [Related]
2. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Radich JP; Mauro MJ
Hematol Oncol Clin North Am; 2017 Aug; 31(4):577-587. PubMed ID: 28673389
[TBL] [Abstract][Full Text] [Related]
6. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of tyrosine kinase therapy in CML.
Mahon FX
Ann Hematol; 2015 Apr; 94 Suppl 2():S187-93. PubMed ID: 25814085
[TBL] [Abstract][Full Text] [Related]
10. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
12. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
Nasr R; Bazarbachi A
Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
[TBL] [Abstract][Full Text] [Related]
13. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
14. The Role of Early Molecular Response in the Management of Chronic Phase CML.
Harrington P; Kizilors A; de Lavallade H
Curr Hematol Malig Rep; 2017 Apr; 12(2):79-84. PubMed ID: 28405921
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia.
Yeung DT; Hughes TP
Crit Rev Oncog; 2012; 17(1):17-30. PubMed ID: 22471662
[TBL] [Abstract][Full Text] [Related]
16. Novel combination treatments targeting chronic myeloid leukemia stem cells.
Al Baghdadi T; Abonour R; Boswell HS
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):94-105. PubMed ID: 22178144
[TBL] [Abstract][Full Text] [Related]
17. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
18. Response-related predictors of survival in CML.
Hanfstein B; Müller MC; Hochhaus A
Ann Hematol; 2015 Apr; 94 Suppl 2():S227-39. PubMed ID: 25814089
[TBL] [Abstract][Full Text] [Related]
19. Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Burchert A
Curr Hematol Malig Rep; 2014 Mar; 9(1):9-16. PubMed ID: 24500518
[TBL] [Abstract][Full Text] [Related]
20. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
Lau A; Seiter K
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]